Avellino Labs announced the strategic addition of James V. Mazzo to its board of directors. The partnership will further anchor Avellino Lab’s leadership in developing the science and setting the standard of genetic testing in ophthalmology, according to a company news release.
Mr. Mazzo joins the Avellino Labs Board of Directors with over 38 years of experience in ophthalmology.
“Jim’s [Mazzo] knowledge of the ophthalmic community underscores our mission to collaborate closely with eye care professionals to provide them with the solutions they need to best serve their patients,” Avellino Labs Chairman of the Board Gene Lee said in the news release. “We believe his expertise will strengthen our efforts as we partner with clinical and scientific experts to advance the science of genetic testing and gene therapy in ophthalmology.”
Mr. Mazzo is currently the Global President of Ophthalmic Devices at Carl Zeiss Meditec. He also serves on the ASCRS Governing Board, the AAO Foundation Advisory Board, and is an Executive Committee Member of the Medical Device Manufacturers Association (MDMA). Throughout his career, Mr. Mazzo has held various executive and board leadership roles at ophthalmic organizations, including Allergan, Advanced Medical Optics, Abbott, AcuFocus, Neurotech and AdvaMed.
“Avellino Labs is the future of personal medicine in ophthalmology,” said Mr. Mazzo. “I’m looking forward to working alongside these visionaries, as well as ophthalmic and optometric providers, to create new opportunities for earlier detection of diseases, leading to greater treatment options and overall better patient care.”